Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward.

Drug-coated balloons an effective tool in the battle against femoropopliteal disease
Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.
Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients
The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas.
Out on a Limb: Tackling the PAD Knowledge Gap to Save Legs & Lives
Peripheral artery disease is under scrutiny as the number of endovascular interventions has soared. In a field where clinical evidence is sparse, experts are asking how the financial and societal costs of revascularization compare with amputating the problem and whether early detection and treatment could save lives, limbs and perhaps healthcare dollars.
Data Drought: The Struggle to Build Evidence in Vascular Medicine & Intervention
How VIVA Physicians is working to answer questions about treatment of vascular disease.
VIVA.14: Promising 1-year results for drug-coated balloons in diabetics
Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

Researchers said they were surprised to learn that "no pain, no gain" was so accurate for patients with peripheral artery disease (PAD). A news study found patients should push past the pain because it improves outcomes.

VIVA.14: Promising 1-year results for drug-coated balloons in diabetics

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

November 10, 2014

VIVA.14: Zilver PTX holds strong at five years

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

November 7, 2014

VIVA.14: DISRUPT PAD brings lithoplasty technique to peripheral lesions

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis.

November 6, 2014

Covidien announces 12-month DEFINITIVE AR results at VIVA 2014

Covidien announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

November 6, 2014

AccessClosure announces distribution agreement for the FLASH Ostial System

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.

October 16, 2013

Quality of life improves dramatically following stenting in patients with peripheral artery disease

Data from a study led by researchers at Saint Luke's Mid America Heart Institute<http://globalmessaging1.prnewswire.com/clickthrough/servlet/clickthrough?msg_id=7563978&adr_order=59&url=aHR0cDovL3d3dy5zYWludGx1a2VzaGVhbHRoc3lzdGVtLm9yZy9zZXJ2aWNlcy9oZWFydC1hbmQt%0AdmFzY3VsYXItY2FyZGlvdmFzY3VsYXItc2VydmljZXM%3D> showed marked, long-term improvement in health status in patients suffering from peripheral artery disease treated with the S.M.A.R.T. Nitinol Self-Expandable Stent. The study was sponsored by Cordis Corporation, (Fremont, Calif.), manufacturer of the S.M.A.R.T. Stent.

October 9, 2013

ED as a Vascular Disease: Stents & Interventions

Stenting stenosis in the internal pudendal artery as a treatment for erectile dysfunction (ED) appears to be safe and effective, but more needs to be understood about disease prevalence and pelvic vasculature, cardiologists say. More immediate is leveraging ED to reduce cardiovascular risk factors.

December 19, 2011

Around the web

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business

What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."